NASDAQ · EWTX
Healthcare · Biotechnology
$43.63
Down-$0.99 (-2.22%)
Updated Sep 16, 2026, 12:03 PM
SID Score
6.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
EWTX closed at $43.63 after 20 trading sessions, down 1.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $44.69 | $45.02 | $42.61 | $43.63 | 2.97M |
| Sep 14, 2026 | $43.98 | $45.70 | $43.95 | $44.62 | 1.1M |
| Sep 11, 2026 | $43.54 | $44.80 | $42.90 | $44.40 | 1.4M |
| Sep 10, 2026 | $42.82 | $43.50 | $42.35 | $42.90 | 788.59K |
| Sep 9, 2026 | $43.03 | $44.30 | $42.97 | $43.39 | 707.9K |
| Sep 8, 2026 | $42.845 | $44.92 | $42.21 | $43.82 | 1.29M |
| Sep 4, 2026 | $41.73 | $43.38 | $41.6034 | $43.07 | 826.75K |
| Sep 3, 2026 | $42.32 | $42.995 | $41.395 | $41.95 | 976.77K |
| Sep 2, 2026 | $42.61 | $43.94 | $40.76 | $41.98 | 1M |
| Sep 1, 2026 | $41.59 | $42.64 | $40.82 | $42.25 | 1.04M |
| Aug 31, 2026 | $42.24 | $42.46 | $40.64 | $41.77 | 1.09M |
| Aug 28, 2026 | $43.84 | $44.19 | $42.72 | $42.76 | 739.78K |
| Aug 27, 2026 | $44.16 | $44.75 | $43.6298 | $44.19 | 995.6K |
| Aug 26, 2026 | $44.21 | $45.05 | $42.911 | $44.38 | 814.07K |
| Aug 25, 2026 | $45.22 | $46.32 | $44.02 | $44.21 | 1.15M |
| Aug 24, 2026 | $43.67 | $45.44 | $42.59 | $44.72 | 1.04M |
| Aug 21, 2026 | $43.54 | $44.675 | $43.00 | $44.18 | 1.25M |
| Aug 20, 2026 | $45.905 | $45.905 | $43.08 | $43.29 | 1.34M |
| Aug 19, 2026 | $45.55 | $46.59 | $44.66 | $46.44 | 2.24M |
| Aug 18, 2026 | $43.17 | $45.29 | $42.62 | $44.11 | 1.52M |
The latest Smart Investors Daily articles mentioning EWTX.
EWTX research
Company profile and research snapshot.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | JP Morgan | Overweight | — |
| Aug 11, 2026 | Goldman Sachs | Neutral | — |
| Jul 20, 2026 | Evercore ISI Group | Outperform | — |
| Jul 9, 2026 | Oppenheimer | Outperform | — |
| Jul 6, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 20, 2026
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $45 to $55.
Benzinga · Feb 27, 2026
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $30 to $45.
Benzinga · Feb 26, 2026
Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.05 percent. This is a 11.9 percent decrease over losses of $(0.42) per share
Yahoo · Feb 13, 2026
Edgewise Therapeutics (NASDAQ:EWTX) highlighted multiple upcoming milestones across its cardiac and neuromuscular programs during a presentation at Guggenheim’s 2026 Healthcare Innovations Conference. Chief Operating Officer Behrad Derakhshan said the company is approaching a “remarkable year” as it
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EWTX.
